CDR132L is an experimental medication being tested in this clinical trial. It is designed to help patients who have a weakened heart function after a heart attack. The medication is given through an intravenous (IV) infusion, which means it is delivered directly into the bloodstream. The goal of CDR132L is to improve the heart’s ability to pump blood by targeting specific molecules in the body that affect heart function. This medication is being studied to see if it can be a helpful addition to the standard treatments that patients are already receiving for their heart condition.

Acute Myocardial Infarction – This condition occurs when blood flow to a part of the heart is blocked for a long enough time that part of the heart muscle is damaged or dies. It is commonly known as a heart attack. The blockage is usually caused by a buildup of fat, cholesterol, and other substances, which form a plaque in the coronary arteries. As the plaque breaks, a blood clot forms, obstructing the blood flow. The affected heart muscle becomes deprived of oxygen, leading to tissue damage. Over time, this can weaken the heart’s ability to pump blood effectively.

Left-Sided Heart Failure – This condition happens when the left side of the heart cannot pump blood efficiently, leading to a buildup of fluid in the lungs. It is often a result of damage to the heart muscle, such as from a heart attack or long-term high blood pressure. As the left ventricle fails to pump blood out to the body, pressure increases in the left atrium and then in the pulmonary veins. This pressure causes fluid to leak into the lung tissues, leading to congestion and breathing difficulties. Over time, the heart may become enlarged as it works harder to meet the body’s demands. This condition can lead to fatigue and reduced ability to exercise.